Ajooni Biotech

Who are the top shareholders of the Ajooni Biotech?

The top shareholder of Ajooni Biotech is Jasjot Singh, holding 11.01%, while individual investors own 65.27% of the shares. The highest public shareholder is Anantharaman Janaki at 1.17%, with no mutual funds or foreign institutional investors involved.

The top shareholders of Ajooni Biotech include Jasjot Singh, who holds the highest stake among promoters at 11.01%. The majority of the company's shares are held by individual investors, accounting for 65.27% of the total holdings. The highest public shareholder is Anantharaman Janaki, with a holding of 1.17%. There are no mutual funds or foreign institutional investors currently holding shares in the company, and there are no pledged promoter holdings.

What does Ajooni Biotech do?

Ajooni Biotech Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 29 Cr and a net profit of 2 Cr for the quarter ending March 2025. It was incorporated in 2010 and transitioned to a public company in 2017.

Overview:<BR>Ajooni Biotech Ltd operates in the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap company.<BR><BR>History:<BR>Ajooni Biotech Ltd was originally incorporated as a Private Limited Company on 17th February 2010. It transitioned to a Public Limited Company and changed its name on 27th September 2017. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 29 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 2 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 97 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 29.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.18 <BR>Return on Equity: 3.85% <BR>Price to Book: 1.13 <BR><BR>Contact Details:<BR>Address: D-118 Industrial Area, Phase-7 Mohali Punjab : 160059 <BR>Tel: 91-172-5020758-69 <BR>Email: info@ajoonibiotech.com <BR>Website: http://www.ajoonibiotech.com

Who are in the management team of Ajooni Biotech?

As of March 2023, the management team of Ajooni Biotech includes Jasjot Singh (Executive Director/Managing), Gursimran Singh (Executive Director & Wholetime Director), Partek Singh (Executive Director), and independent directors Ramandeep Singh, Imteshwar Singh, and Simmi Chhabras. Each member contributes to the company's governance and strategic direction.

As of March 2023, the management team of Ajooni Biotech includes the following individuals:<BR><BR>1. Jasjot Singh - Executive Director / Managing<BR>2. Gursimran Singh - Executive Director & Wholetime Director<BR>3. Partek Singh - Executive Director<BR>4. Ramandeep Singh - Independent Director<BR>5. Imteshwar Singh - Independent Director<BR>6. Simmi Chhabras - Independent Director<BR><BR>Each member plays a significant role in the company's governance and strategic direction.

When is the next results date for Ajooni Biotech?

No Upcoming Board Meetings

What is the bonus history of the Ajooni Biotech?

Ajooni Biotech issued a 1:9 bonus on March 10, 2021, with a record date of March 12, 2021, meaning shareholders received 1 additional share for every 9 shares held.

Ajooni Biotech has a bonus history that includes a 1:9 bonus issue announced on March 10, 2021. The record date for this bonus was March 12, 2021. This means that for every 9 shares held, shareholders received 1 additional share as a bonus.

Has Ajooni Biotech declared dividend?

No Dividend History Available

Is Ajooni Biotech overvalued or undervalued?

As of May 27, 2025, Ajooni Biotech's valuation has improved to attractive, indicating it is undervalued with a PE ratio of 28.81, an EV to EBITDA of 22.14, and a Price to Book Value of 1.11, suggesting potential for growth despite recent underperformance against the Sensex.

As of 27 May 2025, Ajooni Biotech's valuation grade has moved from fair to attractive, indicating a positive shift in its perceived worth. The company appears to be undervalued based on its current metrics. Key ratios include a PE ratio of 28.81, an EV to EBITDA of 22.14, and a Price to Book Value of 1.11, which suggest that the stock is trading at a reasonable price relative to its earnings and assets.<BR><BR>In comparison to its peers, Ajooni Biotech's PE ratio is similar to that of its closest competitor, while the industry average for EV to EBITDA is typically lower, indicating potential for growth. Notably, Ajooni Biotech's PEG ratio is at 0.00, which may suggest that the stock is undervalued relative to its growth prospects. Despite recent underperformance against the Sensex, particularly over the past year and three years, the long-term return of 395.19% over five years highlights its potential for recovery and growth.

What is the technical trend for Ajooni Biotech?

As of June 3, 2025, Ajooni Biotech's technical trend is bearish, with dominant bearish signals from MACD, Bollinger Bands, and moving averages, despite a mildly bullish weekly RSI.

As of 3 June 2025, the technical trend for Ajooni Biotech has changed from mildly bearish to bearish. The current stance is bearish with a strong emphasis on the weekly and monthly MACD and Bollinger Bands, both indicating bearish conditions. The daily moving averages also confirm a bearish trend. Although the weekly RSI shows bullish momentum, it is overshadowed by the overall bearish signals from other indicators. The KST remains bearish on the weekly and mildly bearish on the monthly, while the Dow Theory presents a mildly bullish view on the weekly but no trend on the monthly. Overall, the bearish indicators dominate, suggesting a weak market sentiment for Ajooni Biotech.

Who are the peers of the Ajooni Biotech?

Ajooni Biotech's peers include Ind-Swift, Onyx Biotec, Bharat Immunolog, and others. Ind-Swift shows the highest 1-year return, while Ajooni Biotech has a -12.54% return, indicating lower performance compared to its peers.

Peers: The peers of Ajooni Biotech are Ind-Swift, Onyx Biotec, Bharat Immunolog, Source Natural, Mercury Labs, Samrat Pharma, Achyut Healthcar, Rajnish Wellness, Parnax Lab, and Makers Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Source Natural and Samrat Pharma, while Average management risk is found at Onyx Biotec and Rajnish Wellness, and the rest have Below Average management risk. Growth is Excellent at Onyx Biotec and Rajnish Wellness, while Good growth is seen at Parnax Lab, and the rest have Below Average growth. Average capital structure is noted at Ajooni Biotech, while Excellent capital structure is present at Mercury Labs and Samrat Pharma, and the rest have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Ind-Swift at N/A, while Ajooni Biotech has a 1-year return of -12.54%, indicating a lower performance compared to its peers. Additionally, Ind-Swift, Onyx Biotec, and Ajooni Biotech have negative six-month returns.

How big is Ajooni Biotech?

As of 24th July, Ajooni Biotech Ltd has a market capitalization of 96.00 Cr, with recent net sales of 114.68 Cr and a net profit of 3.36 Cr. The company reported shareholder's funds of 42.71 Cr and total assets of 47.21 Cr for the annual period ending in March 2024.

As of 24th July, Ajooni Biotech Ltd has a market capitalization of 96.00 Cr, classified as a Micro Cap.<BR><BR>In the latest four quarters, Ajooni Biotech reported Net Sales of 114.68 Cr and a Net Profit of 3.36 Cr.<BR><BR>For the latest annual period ending in March 2024, the company had Shareholder's Funds of 42.71 Cr and Total Assets amounting to 47.21 Cr.

How has been the historical performance of Ajooni Biotech?

Ajooni Biotech has shown significant growth in net sales and profit, with net sales increasing from 39.72 crore in March 2019 to 114.69 crore in March 2025, and profit after tax rising from 0.41 crore to 3.37 crore. However, cash flow from operating activities turned negative in March 2025, indicating challenges in cash management.

Answer:<BR>The historical performance of Ajooni Biotech shows significant growth in net sales and profit over the years, with the latest figures for March 2025 indicating net sales of 114.69 crore and a profit after tax of 3.37 crore.<BR><BR>Breakdown:<BR>Ajooni Biotech's net sales have steadily increased from 39.72 crore in March 2019 to 114.69 crore in March 2025, reflecting a strong upward trend. The total operating income has followed a similar trajectory, reaching 114.69 crore in March 2025, up from 40.06 crore in March 2019. The company's operating profit, excluding other income, also improved, showing a rise to 3.68 crore in March 2025 from 0.89 crore in March 2019. Profit before tax has increased to 4.33 crore in March 2025, compared to 0.47 crore in March 2019, while profit after tax reached 3.37 crore, up from 0.41 crore in March 2019. The total liabilities of the company rose to 94.67 crore in March 2025 from 22.94 crore in March 2020, indicating a significant expansion in its financial structure. Total assets also increased to 94.67 crore in March 2025, reflecting the growth in both current and non-current assets. However, cash flow from operating activities showed a negative trend in March 2025, with a cash outflow of 17.00 crore, contrasting with a positive inflow of 22.00 crore in March 2024. Overall, Ajooni Biotech has demonstrated robust growth in sales and profitability, despite some challenges in cash flow management in the latest fiscal year.

Are Ajooni Biotech Ltd latest results good or bad?

Ajooni Biotech Ltd's latest results show strong revenue growth of 72.64% and a net profit increase of 126.03%, but concerns about declining profitability margins and weak return ratios indicate mixed performance overall. The stock has also underperformed significantly, raising questions about investor confidence.

Ajooni Biotech Ltd's latest results present a mixed picture. On the positive side, the company reported a significant revenue growth of 72.64% year-on-year, with net sales reaching ₹58.75 crores in Q3 FY26. Additionally, net profit increased by 126.03% compared to the same quarter last year, amounting to ₹1.65 crores. This marks the highest quarterly profit in recent times and reflects strong order execution and market share gains.<BR><BR>However, there are notable concerns regarding profitability margins. The operating margin improved slightly to 5.16%, but the PAT margin decreased to 2.81%, down 12 basis points from the previous quarter. This indicates that while revenue is growing, the company is struggling to convert that growth into sustainable profitability. The overall financial health is further complicated by weak return ratios, with a return on equity (ROE) of just 4.00% and return on capital employed (ROCE) at 3.46%, suggesting inefficiencies in capital utilization.<BR><BR>Moreover, the stock has underperformed significantly, trading 46.65% lower over the past year, which raises concerns about investor confidence and the company's market positioning. The absence of institutional investors also reflects skepticism about the company's quality and growth prospects.<BR><BR>In summary, while Ajooni Biotech has demonstrated impressive revenue growth, the challenges in profitability and investor sentiment suggest that the latest results are not entirely positive.

Should I buy, sell or hold Ajooni Biotech Ltd?

Which are the latest news on Ajooni Biotech?

Why is Ajooni Biotech Ltd falling/rising?

As of 08-May, Ajooni Biotech Ltd's stock price is stable at 4.30, with a slight weekly rise of 2.38% but a yearly decline of 23.49%. Despite strong operating profit growth and increased investor interest, the stock's long-term performance and trading position indicate potential challenges for significant price appreciation.

As of 08-May, Ajooni Biotech Ltd's stock price is currently stable at 4.30, showing no change (0.00%). The stock has experienced a mixed performance over various periods, with a slight rise of 2.38% over the past week, while it has seen a decline of 23.49% over the past year. Despite this decline, the company has reported significant growth in operating profit of 153.79% and has declared positive results for the last six consecutive quarters, indicating strong operational performance.<BR><BR>Investor participation has increased, with delivery volume rising by 97.32% against the 5-day average, suggesting growing interest in the stock. However, the stock is trading below its longer-term moving averages, which may indicate a lack of momentum for sustained price increases. Additionally, while the company has a very attractive valuation with a low PEG ratio of 0.2 and is trading at a discount compared to its peers, it also faces challenges due to weak long-term fundamental strength, reflected in an average ROCE of 5.00%.<BR><BR>Overall, while there are positive indicators such as improved operating profits and rising investor participation, the stock's long-term performance and current trading position suggest that it is facing challenges that could hinder significant price appreciation in the near term.